<DOC>
	<DOCNO>NCT02497001</DOCNO>
	<brief_summary>Study Assess Efficacy Safety PT010 , PT003 , PT009 Compared With Symbicort® Turbuhaler® Subjects Moderate Very Severe Chronic Obstructive Pulmonary Disease .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Parallel-Group , 24-Week , Chronic-Dosing , Multi-Center Study Assess Efficacy Safety PT010 , PT003 , PT009 Compared With Symbicort® Turbuhaler® ( Kronos )</brief_title>
	<detailed_description>A Randomized , Double-Blind , Parallel-Group , 24-Week , Chronic-Dosing , Multi-Center Study Assess Efficacy Safety PT010 , PT003 , PT009 Compared With Symbicort® Turbuhaler® Active Control Subjects Moderate Very Severe Chronic Obstructive Pulmonary Disease This study include follow 3 sub-studies : 12-hour Pulmonary Function Test ( PFT ) , Pharmacokinetic ( PK ) Profile , Hypothalamic-pituitary-adrenal Axis .</detailed_description>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion Criteria Given sign write informed consent participate . Nonchild bear potential ( ie , physiologically incapable become pregnant , include female 2 year postmenopausal ) ; Child bear potential , negative serum pregnancy test Visit 1 , agree acceptable contraceptive method use consistently correctly duration study . Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) , local applicable guideline . Current former smoker history least 10 packyears cigarette smoking . Forced expiratory volume 1 second ( FEV1 ) /Forced vital capacity ( FVC ) ratio must &lt; 0.70 FEV1 must &lt; 80 % predict normal value calculate use NHANES III reference equation ( reference norm applicable region ) . Required COPD maintenance therapy : All Subjects must two inhaled maintenance therapy management COPD least 6 week prior Screening . Scheduled SABA and/or schedule SAMA consider inhaled maintenance therapy Please refer study protocol complete inclusion criterion list . Exclusion Criteria Significant diseases condition COPD , , opinion Investigator , may put subject risk participation study may influence either result study subject 's ability participate study . Women pregnant lactating , plan become pregnant course study , woman childbearing potential use acceptable method contraception . Subjects , opinion Investigator , current diagnosis asthma . Subjects hospitalize due poorly control COPD within 3 month prior Visit 1 ( Screening ) Screening Period Subjects poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior Visit 1 ( Screening ) Screening Period Immune suppression severe neurological disorder affect control upper airway risk factor opinion Investigator would put subject substantial risk pneumonia . Subjects diagnosis narrow angle glaucoma , , opinion Investigator , adequately treat . Subjects history hypersensitivity β2agonists , budesonide corticosteroid component , glycopyrronium muscarinic anticholinergic , component IMPs . Please refer study protocol complete inclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>